58,725 Shares in Caris Life Sciences, Inc. $CAI Acquired by Hamilton Lane Advisors LLC

Hamilton Lane Advisors LLC bought a new stake in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 58,725 shares of the company’s stock, valued at approximately $1,584,000. Caris Life Sciences makes up about 0.9% of Hamilton Lane Advisors LLC’s portfolio, making the stock its 13th biggest position.

A number of other institutional investors and hedge funds have also made changes to their positions in CAI. Olistico Wealth LLC purchased a new stake in shares of Caris Life Sciences during the 4th quarter worth $31,000. Diversified Trust Co. bought a new stake in Caris Life Sciences during the fourth quarter valued at about $540,000. Finally, Zevenbergen Capital Investments LLC purchased a new position in Caris Life Sciences in the fourth quarter valued at about $14,655,000.

Caris Life Sciences Stock Performance

NASDAQ:CAI opened at $19.29 on Friday. The firm has a market capitalization of $5.45 billion and a P/E ratio of -107.17. The company has a quick ratio of 7.35, a current ratio of 7.85 and a debt-to-equity ratio of 0.66. Caris Life Sciences, Inc. has a 12 month low of $16.28 and a 12 month high of $42.50. The business’s fifty day moving average is $20.19.

Caris Life Sciences (NASDAQ:CAI) last issued its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The firm had revenue of $292.89 million during the quarter, compared to analysts’ expectations of $281.00 million. During the same quarter last year, the business earned ($1.73) EPS. The business’s revenue was up 125.4% on a year-over-year basis.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Robert W. Baird increased their price target on shares of Caris Life Sciences from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Canaccord Genuity Group cut their price objective on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research report on Friday, March 13th. The Goldman Sachs Group assumed coverage on shares of Caris Life Sciences in a research note on Wednesday. They set a “buy” rating and a $27.00 price objective for the company. BTIG Research decreased their target price on shares of Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, Evercore set a $38.00 target price on shares of Caris Life Sciences in a research note on Monday, January 5th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Caris Life Sciences currently has an average rating of “Hold” and a consensus price target of $30.60.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.